FDA Approves Amgen Colon Cancer Drug
The Food and Drug Administration cleared Vectibix as a treatment for advanced colon cancer, the agency announced Wednesday. Vectibix is the first of nearly a dozen drugs currently under development at Amgen, the world’s largest Biotechnology company.
Analysts predict that doctors will begin treating colon cancer, the third most common form of cancer in American men and women, with Vectibix (also known as panitumumab) quickly, with over $300M in sales expected in the first year.
Approximately 110,000 adults are expected to be diagnosed with colon cancer next year, and over 55,000 will likely die.